Trevi Therapeutics (TRVI) has caught the attention of investors after recent updates on its chronic cough clinical programs. The company is moving ahead with Phase 3 plans for IPF-related chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback